{"name":"Meletios A. Dimopoulos","slug":"meletios-a-dimopoulos","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Bortezomib, Rituximab, Dexamethasone","genericName":"Bortezomib, Rituximab, Dexamethasone","slug":"bortezomib-rituximab-dexamethasone","indication":"Multiple myeloma","status":"phase_2"}]}],"pipeline":[{"name":"Bortezomib, Rituximab, Dexamethasone","genericName":"Bortezomib, Rituximab, Dexamethasone","slug":"bortezomib-rituximab-dexamethasone","phase":"phase_2","mechanism":"Proteasome inhibitor","indications":["Multiple myeloma","Mantle cell lymphoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQSmstWHBpSEN6dVNWNi1EZ2hScmRyNmUwRWhTLV93dUtpZ1BYOG9RaU5TTU5wM3lxYk00VXBWY0YtOE4zbk9UZS1PYlY4VVFmX3ZVWDA3TDU4cHJnZ3hSemdhRjZwNVE4aHc1TjhBVnkyUWhKVy1IWndNdXphLTNsN3prY0s0NnNvcnQxRmpraWhIOS0zNkZMNmxB?oc=5","date":"2025-07-24","type":"pipeline","source":"pharmaphorum","summary":"EC clears first treatment for high-risk smouldering multiple myeloma - pharmaphorum","headline":"EC clears first treatment for high-risk smouldering multiple myeloma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE12T29weE9qQVA5MmVEMk5HRFJjVDNXaTFNWlRwb3lxRWM5VGhnQ3hJNUNmUmd2WUNnQ1FQdHZMMVhyMDdBd2N3djhtLWNSeDdpTW9nYXVxUm1EUnJLWkZr?oc=5","date":"2025-07-07","type":"pipeline","source":"nature.com","summary":"EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma - nature.com","headline":"EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNcFFrZ1pHMlM1ZnUwWGJ4eS0ydVQyRXB3bURCTHRodVdwZmJSSUE2TTlOU2NMQVZHaGgyZk8zR01zb1NlNFNMUGtNbTF2d1hPNF96c3RnaDZrTmptTEdvRURrTVR1RkhxNDFsb3JkbW1uM01SbXBTRVp4ZXRZTUl6bU9PRkJRWUZmZHBmN3dzTDRQN1RITmMxVkFiWTVZLUZ2MzhCVA?oc=5","date":"2025-06-15","type":"pipeline","source":"OncLive","summary":"Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma - OncLive","headline":"Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOYkJWcXlRd3FiaUY0ZUlaaG5KQV9NMFYySzlja3hOS042LVdQWG5XZlo5NkFTZGdQSnQ1N0RKVUl6QVVUYW5Ic245SnVNODVmaFREemExbk90TFo4UF9NWWtrYVB2Ty1mRER6Q253U1BpSzBjOWhTX3JOWWZIVm1yQmRCdjNZUmcwZ1ZoVkE0azZzTGliMW1naDU5ZkNMa3Q5QmJwZndBZkVibHlHVVhmNmY5U3VNZw?oc=5","date":"2024-12-23","type":"pipeline","source":"ASCO Daily News","summary":"Sequencing Anti-BCMA Therapies in Multiple Myeloma: What Is Their Optimal Use With Other Available Treatment Options? - ASCO Daily News","headline":"Sequencing Anti-BCMA Therapies in Multiple Myeloma: What Is Their Optimal Use With Other Available Treatment Options?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE5IaEI5Z3JzVkc3N1VQQUVLNy1PWVZUVVN2V2gxUUVhSXltbDRtMHBLVE5HMDZwUElhXzZFY2tMSEhvMUJuR2FrODNGbGtqUTVVdDdOc0RHS2IwbDNrRUVvUQ?oc=5","date":"2023-12-12","type":"pipeline","source":"NEJM","summary":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma - NEJM","headline":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE41MEQzX0dFRkdUaHQ2SHBCdGJoZ0puUkxYZ2hNN2pyTWI4SXc4QjBwTXh3bHUzVmFEcHZma2FPODg1UHpiRXpDTDhLMkhORy1XMnhOYzc1QWx4TDBCc19HbzRMTkRyNlBadm1wQlQ3Mm40M1d5c2pWaQ?oc=5","date":"2023-10-31","type":"pipeline","source":"Hub ΕΚΠΑ","summary":"4th International Congress on Pharmacogenomics and Personalized Diagnosis and Therapy Precision Medicine in Disease, Diagnosis and Therapy 2023 [1-3/12/23] - Hub ΕΚΠΑ","headline":"4th International Congress on Pharmacogenomics and Personalized Diagnosis and Therapy Precision Medicine in Disease, Dia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE9obE1tZjNXcmxiSXphOTYxYUlxWGFxcG1vczlaUU5jTVVjMmV4WUxSaENCVHBUZ0N3ck4yeTV3MlFLWjdJSGJjQUpIM0NWSGR6MW9hY0pCNTNva1F4Vnc?oc=5","date":"2020-04-23","type":"pipeline","source":"nature.com","summary":"Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma - nature.com","headline":"Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant ma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNSVlNZ3NkWjlDUUtDMHZOQndhNWY5U3J1dUpSZjdkYmFQR1JoOG02ZWhWX3lrTlpGSlc4c0VuZlkzZmxaX2xhYUIwVHZRQTRlYnpkSDdDQUkzdC1femJHZ1pmY0hvZVFKVmZfc3RXa09HbFhjZUQ4aDUxTmY0SG9YV2dLNmdFdVdNNEx0YjNrYXNXUlVYOUMyTGFlWDFjaUdkZkxqbkFmLUtkYjlKb3hUUUZ2RQ?oc=5","date":"2018-06-18","type":"trial","source":"Fierce Pharma","summary":"Bristol-Myers, AbbVie eye new use for myeloma drug Empliciti after phase 2 combo win - Fierce Pharma","headline":"Bristol-Myers, AbbVie eye new use for myeloma drug Empliciti after phase 2 combo win","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE1XdEdXel9Sb3hGVVlaQTZyMERSWkthMmZaUGdDeG5yem9mQkdBR0ZUVjJPcXJwNVV2U25YS3o4LXRyUFY3WjZBcEM5dEZLbWZoQS1FXzlCaXFRT1QxRk1ONw?oc=5","date":"2016-10-06","type":"pipeline","source":"NEJM","summary":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma - NEJM","headline":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxON1NfMkE5bFBlS0daY1lOWlFtSVc0dE4zVml5Z3VPTWREcFU1VUR1U0dXRkJtaU5fTHNKYjhFX09paUIyVl9RMzZRbkNGeUFldTdHcmR4bzQ2TDVnTEs1ekk5WlVRa1BCdUlmZ3JqSFducWZYZlh5SmRxS0h0Q2I0NkxxdFJFaEkxdmY3VTVR?oc=5","date":"2015-12-05","type":"trial","source":"Pharmafile","summary":"Amgen’s Kyprolis doubles Velcade benefit in head-to-head study - Pharmafile","headline":"Amgen’s Kyprolis doubles Velcade benefit in head-to-head study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE5SRktOdHFLb0oxNmxINzQxODdKcFRCekhPcWhvZ3FZckV4Q25ZVElpXzhkRVpyaEdxbml1ZWpFZUJPU0tWZ3pseVUtS2pWalFZOV9hQlNVMUl5eU9TNDZLSw?oc=5","date":"2014-12-06","type":"pipeline","source":"NEJM","summary":"Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma - NEJM","headline":"Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE9HNTd3V3hjQTU2LWRlb2NOZ0dJMFZDLXV3WTI1MnY3aDlESzdVTUlyMXVrbXNRTUlmVERkX3FkUGQ0bVRCQ2UySzhLUGpuTGhhNzdFeVZ1MmRGV290cHdveg?oc=5","date":"2008-08-28","type":"pipeline","source":"NEJM","summary":"Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma - NEJM","headline":"Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":7,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}